- •Offer BRCA genetic testing to all invasive epithelial OC patients (excluding borderline and mucinous cancers).
- •Testing should be irrespective of age.
- •Ideally offer testing at diagnosis, although patients can be referred at any stage.
- •Retrospective testing should be offered to patients in long-term follow-up.
- •Tumour testing should be considered in non-germline-mutated patients.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.Eur J Cancer. 2013; 49: 1374-1403
- Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.Clin Cancer Res. 2015; 21: 211-220
- Uterine Cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations.JAMA Oncol. 2016 Jun 30; ([Epub ahead of print])https://doi.org/10.1001/jamaoncol.2016.1820
- Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review.Adv Ther. 2016; 33: 129-150
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.Ann Oncol. 2016; 27: 1449-1455
- Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study).J Clin Oncol. 2016; 34 (abstr 5544)
- Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube and peritoneal carcinomas.Clin Cancer Res. 2014; 20: 764-775
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in randomised phase 2 trial.Lancet Oncol. 2015; 15: 852-861
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J Clin Oncol. 2012; 30: 2654-2663
- Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.Sci Rep. 2016 Jul 13; 6: 29506https://doi.org/10.1038/srep29506
- BRCA in breast cancer: ESMO clinical practice guidelines.Ann Oncol. 2010; 21: v20-v22
- Genetic/familial high-risk assessment: breast and Ovarian. Version 2.NCCN.org, 2015 (Available at:)[Accessed June 2016])
- SGO clinical practice statement: genetic testing for ovarian cancer. 2014[Accessed June 2016])
- AGO Austria recommendations for genetic testing of patients with ovarian cancer.Wien Klin Wochenschr. 2015; 127: 652-654
- Therapy-orienting testing of BRCA1 and BRCA2 germline mutations in women with ovarian cancer.Belg J Med Oncol. 2015; 9: 65-70
- [Recommended extension of indication criteria for genetic testing of BRCA1 and BRCA2 mutations in hereditary breast and ovarian cancer syndrome].Klin Onkol. 2016; 29: S9-S13
- Care guidelines. Ovarian cancer. 2012 (Available at:)
- Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Future Oncol. 2016; 12 ([Epub ahead of print]): 2071-2075
http://www.ipolisboa.min-saude.pt/Default.aspx?Tag=CONTENT&ContentId=9296 Llort G, Chirivella I.
- SEOM clinical guidelines in hereditary breast and ovarian cancer.Clin Transl Oncol. 2015; 17: 956-961
- Management of epithelial ovarian cancer.SIGN, Edinburgh2013 (SIGN publication no. 135). [November 2013]. Available from: URL:
- Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations.2015 (Available at:)https://www.engage.england.nhs.uk/consultation/specialised-services-consultation/user_uploads/brca-policy.pdf
- Inherited mutations in women with ovarian carcinoma.JAMA Oncol. 2015; ([Epub ahead of print]): 1-9https://doi.org/10.1001/jamaoncol.2015.5495
- Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital based cohort.Genet Med. 2007; 9: 173-179
- One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.Eur J Cancer. 2004; 40: 422-428
- BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.Clin Cancer Rev. 2008; 14: 3761-3767
- Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario.Can J Natl Cancer Inst. 2006; 98: 1694-1706
- Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.Clin Cancer Res. 2015; 21: 652-657
- The integration of BRCA testing into oncology clinics.Br J Nurs. 2016; 25: 690-694
- Randomized noninferiority trial of telephone versus in-person genetic counselling for hereditary breast and ovarian cancer.J Clin Oncol. 2014; 32: 18-26
- Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Eur J Cancer. 2016; 53: 51-64
- Final results of ARIEL2 (part 1): a phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis.Eur Cancer Congr. 2015; 51: s531